Scemblix (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Asciminib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ASSURE-3
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 09 Apr 2024 Planned End Date changed from 15 Oct 2026 to 15 Dec 2026.
- 09 Apr 2024 Planned primary completion date changed from 15 Oct 2026 to 15 Dec 2026.
- 09 Apr 2024 Status changed from not yet recruiting to recruiting.